Literature DB >> 17105857

Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.

J Ogawa, M Harigai, T Akashi, K Nagasaka, F Suzuki, S Tominaga, N Miyasaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17105857      PMCID： PMC1798471          DOI： 10.1136/ard.2006.054197

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.

Authors:  H Kimura; Y Hoshino; H Kanegane; I Tsuge; T Okamura; K Kawa; T Morishima
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

Review 2.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

Review 3.  Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection.

Authors:  Motohiko Okano; Keisei Kawa; Hiroshi Kimura; Akihiro Yachie; Hiroshi Wakiguchi; Akihiko Maeda; Shosuke Imai; Shouichi Ohga; Hirokazu Kanegane; Shigeru Tsuchiya; Tomohiro Morio; Masaaki Mori; Shumpei Yokota; Shinsaku Imashuku
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

4.  IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.

Authors:  M Okada; M Kitahara; S Kishimoto; T Matsuda; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

Review 5.  The molecular biology of interleukin 6 and its receptor.

Authors:  T Kishimoto; M Hibi; M Murakami; M Narazaki; M Saito; T Taga
Journal:  Ciba Found Symp       Date:  1992

6.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors:  Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Arthritis Rheum       Date:  2004-06

7.  Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.

Authors:  Barbara Savoldo; M Helen Huls; Zhensheng Liu; Takayuki Okamura; Hans-Dieter Volk; Petra Reinke; Robert Sabat; Nina Babel; James F Jones; Jennifer Webster-Cyriaque; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 8.  The paradigm of IL-6: from basic science to medicine.

Authors:  Tetsuji Naka; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Arthritis Res       Date:  2002-05-09
  8 in total
  5 in total

Review 1.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

2.  Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.

Authors:  Ryuji Koike; Masayoshi Harigai; Tatsuya Atsumi; Koichi Amano; Shinichi Kawai; Kazuyoshi Saito; Tomoyuki Saito; Masahiro Yamamura; Tsukasa Matsubara; Nobuyuki Miyasaka
Journal:  Mod Rheumatol       Date:  2009-07-10       Impact factor: 3.023

3.  Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study.

Authors:  Nathalie Balandraud; Gaetan Texier; Emmanuel Massy; Olivier Muis-Pistor; Marielle Martin; Isabelle Auger; Marie-Caroline Guzian; Sandrine Guis; Thao Pham; Jean Roudier
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

4.  Rheumatoid Arthritis Complicated with Nasal Septum Perforation Due to Methotrexate-associated Lymphoproliferative Disorder.

Authors:  Ryuki Sakaguchi; Keita Fujikawa; Momoko Okamoto; Emi Matsuo; Kohei Matsumoto; Tomohisa Uchida; Kawashiri Shin-Ya; Masahiro Nakashima; Akinari Mizokami; Atsushi Kawakami
Journal:  Intern Med       Date:  2019-07-10       Impact factor: 1.271

5.  Review of tocilizumab in the treatment of rheumatoid arthritis.

Authors:  Yasuaki Okuda
Journal:  Biologics       Date:  2008-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.